CN1861184A - Application of composition for preparing medicine to treat chilblain disease - Google Patents

Application of composition for preparing medicine to treat chilblain disease Download PDF

Info

Publication number
CN1861184A
CN1861184A CN 200510025689 CN200510025689A CN1861184A CN 1861184 A CN1861184 A CN 1861184A CN 200510025689 CN200510025689 CN 200510025689 CN 200510025689 A CN200510025689 A CN 200510025689A CN 1861184 A CN1861184 A CN 1861184A
Authority
CN
China
Prior art keywords
radix
parts
rhizoma
portions
chilblain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510025689
Other languages
Chinese (zh)
Other versions
CN100444887C (en
Inventor
韦飞燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGXI HUAHONG PHARMACEUTICAL LLC
Shanghai Fosun Pharmaceutical Group Co Ltd
Original Assignee
GUANGXI HUAHONG PHARMACEUTICAL LLC
Shanghai Fosun Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGXI HUAHONG PHARMACEUTICAL LLC, Shanghai Fosun Pharmaceutical Group Co Ltd filed Critical GUANGXI HUAHONG PHARMACEUTICAL LLC
Priority to CNB2005100256894A priority Critical patent/CN100444887C/en
Publication of CN1861184A publication Critical patent/CN1861184A/en
Application granted granted Critical
Publication of CN100444887C publication Critical patent/CN100444887C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

An application of the composition composed of 21 Chinese-medicinal materials including aucklandia root, etc in preparing the medicines for treating the chilblain is disclosed. It has high curative effect (94.4-98.9%).

Description

The application of a kind of compositions in preparation treatment chilblain disease medicine
Technical field
The present invention relates to the new purposes of a kind of Chinese medicine composition, relate to a kind of application of pharmaceutical composition in the treatment chilblain disease that constitutes by Chinese medicines such as the Radix Aucklandiae specifically.
Background technology
Chilblain is meant that human body is subjected to it is attacked by the cold and evil, stagnation of QI-blood, thus cause the damage of locality or general.The person of freezing, the heresy of impression cold also.Skin ulcer person, wound also.
Theory of Chinese medical science thinks that chilblain is that integumentary musculature is attacked by severe cold, and QI-blood circulation does not freely cause coagulation of QI-blood and forms, and the weak or overfatigue of QI and blood is freezing heat cruelly usually, and sudden high fever to freeze primary disease is generated.So the tcm clinical practice treatment is with dispelling cold by warming the meridian, blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain are main.
At present, also effectively not reliable medicine is used for the treatment of chilblain, adopts physiotherapy usually, and as hot compress, massage etc. are controlled table not effect a permanent cure, and can not solve patient's pain at all.
" the reducing swelling and alleviating pain pharmaceutical composition " of open report can suppress the growth of staphylococcus aureus, beta hemolytic streptococcus, escherichia coli, Bacillus typhi, vibrio cholera etc. in the 12 of Ministry of Health of the People's Republic of China's " drug standard " (Chinese traditional patent formulation preparation).Usually only be used for to the killing of pathogenic bacterium, to reach the purpose of reducing swelling and alleviating pain.Can use it for the treatment chilblain,, have bigger clinical value to expand its range of application.
Summary of the invention
The technical issues that need to address of the present invention are to disclose the application of a kind of Chinese medicine compositions in the treatment chilblain, to overcome the defective that prior art exists, expand the purposes of reducing swelling and alleviating pain pharmaceutical composition.
The composition of said Chinese medicine compositions has been open report in the 12 of Ministry of Health of the People's Republic of China's " drug standard " (Chinese traditional patent formulation preparation), is the feedstock production that adopts following parts by weight:
1~100 part of 1~100 part of Herba Asari of 1~100 portion of Herba Schizonepetae of 1~100 part of Radix Saposhnikoviae of the Radix Aucklandiae
1~100 part of 1~100 part of Rhizoma Chuanxiong of 1~100 part of Radix Achyranthis Bidentatae of 1~100 part of Ramulus Cinnamomi of Cortex Acanthopancis
1~200 part of 1~100 part of Radix seu Caulis Parabarii of 1~200 part of Rhizoma Curcumae of 1~100 part of Radix Angelicae Dahuricae of Radix Cynanchi Paniculati
1~200 part of 1~300 portion of Caulis Fibraureae of 1~200 portion of Radix Zanthoxyli of 1~300 part of Radix Ardisiae punctatae of DALUOSAN
1~100 part of 1~100 part of Camphora of 1~200 portion of Lignum Aquilariae Resinatum of 1~300 part of rhizoma sparganic of Fructus Gardeniae
1~100 part of Mentholum.
Preferred parts by weight are:
47 parts of 47 parts of Herba Asaris of 47 portions of Herba Schizonepetae of 47 parts of Radix Saposhnikoviaes of the Radix Aucklandiae
47 parts of 47 parts of Rhizoma Chuanxiongs of 47 parts of Radix Achyranthis Bidentataes of 47 parts of Ramulus Cinnamomi of Cortex Acanthopancis
70 parts of 47 parts of Radix seu Caulis Parabarii of 70 parts of Rhizoma Curcumae of 47 parts of Radixs Angelicae Dahuricae of Radix Cynanchi Paniculati
95 parts of 100 portions of Caulis Fibraureaes of 70 portions of Radix Zanthoxylis of 100 parts of Radix Ardisiae punctatae of DALUOSAN
55 parts of 32.5 parts of Camphoras of 70 portions of Lignum Aquilariae Resinatum of 100 parts of rhizoma sparganic of Fructus Gardeniae
55 parts of Mentholums.
Preferred parts by weight are:
Radix Aucklandiae 47g Radix Saposhnikoviae 100g Herba Schizonepetae 47g Herba Asari 47g
Cortex Acanthopancis 100g Ramulus Cinnamomi 47g Radix Achyranthis Bidentatae 47g Rhizoma Chuanxiong 100g
Radix Cynanchi Paniculati 47g Radix Angelicae Dahuricae 70g Rhizoma Curcumae 100g Radix seu Caulis Parabarii 70g
DALUOSAN 100g Radix Ardisiae punctatae 70g Radix Zanthoxyli 100g Caulis Fibraureae 95g
Fructus Gardeniae 100g rhizoma sparganic 100g Lignum Aquilariae Resinatum 32.5g Camphora 60g
Mentholum 65g.
The inventor finds in secular clinical practice, adopts the pharmaceutical composition of above-mentioned feedstock production that chilblain is had therapeutical effect preferably, can be used to prepare the medicine for the treatment of chilblain.
Pharmaceutical composition of the present invention can tincture form be applied in patient's chilblain place, one is for several times, before smearing, earlier the chilblain place is washed with warm water, after smearing, preferably carries out suitable massage.
Term " tincture " refers to the ethanol water of medicine, and wherein, alcoholic acid volumetric concentration is 35~75%, preferred water 51~55%, and more preferably 53%, in the ethanol water, the weight content of active component is 0.5~5%;
Openly reported preparation of drug combination method of the present invention in the 12 of Ministry of Health of the People's Republic of China's " drug standard " (Chinese traditional patent formulation preparation), specifically comprised the steps:
With above 20 simply, except that Camphora, Mentholum, 19 flavors such as all the other Radix Aucklandiae are ground into coarse powder, according to the percolation under fluid extract and the extractum item (an appendix I of Chinese Pharmacopoeia version in 2000 O), with volumetric concentration is that 35~75% ethanol is made solvent, floods after 24~32 hours, with the speed of the about 1~5ml of per minute percolation slowly, the collection liquid of filtering, device is preserved in addition; After getting Camphora, Mentholum and adding ethanol 700g and make dissolving,, leave standstill, filter, promptly with the above-mentioned liquid mixing of filtering.
Animal experiment and clinical observation prove, pharmaceutical composition of the present invention can effectively be treated I degree chilblain, and total obvious effective rate and total effective rate reach 55.6% and 94.4% respectively after treating 7 days; Total obvious effective rate and total effective rate reach 83.3% and 98.9% respectively after treating 14 days.
The specific embodiment
Embodiment 1
Make pharmaceutical composition 6000g:
1, raw material is formed
Radix Aucklandiae 47g Radix Saposhnikoviae 47g Herba Schizonepetae 47g Herba Asari 47g
Cortex Acanthopancis 47g Ramulus Cinnamomi 47g Radix Achyranthis Bidentatae 47g Rhizoma Chuanxiong 47g
Radix Cynanchi Paniculati 47g Radix Angelicae Dahuricae 70g Rhizoma Curcumae 47g Radix seu Caulis Parabarii 70g
DALUOSAN 100g Radix Ardisiae punctatae 70g Radix Zanthoxyli 100g Caulis Fibraureae 95g
Fructus Gardeniae 100g rhizoma sparganic 70g Lignum Aquilariae Resinatum 32.5g Camphora 55g Mentholum 55g
2, method for making:
More than 20 simply, except that Camphora, Mentholum, 19 flavors such as all the other Radix Aucklandiae are ground into coarse powder, according to the percolation under fluid extract and the extractum item (appendix IO of Chinese Pharmacopoeia version in 2000), with volumetric concentration is that 53% ethanol is made solvent, floods after 28 hours, with the speed of the about 3ml of per minute percolation slowly, the collection liquid 5300g that filters, device is preserved in addition; After getting Camphora, Mentholum and adding ethanol 700g and make dissolving,, leave standstill, filter, promptly with the above-mentioned liquid mixing of filtering.
Embodiment 2
Make pharmaceutical composition 10000g:
1, raw material is formed
Radix Aucklandiae 47g Radix Saposhnikoviae 100g Herba Schizonepetae 47g Herba Asari 47g
Cortex Acanthopancis 100g Ramulus Cinnamomi 47g Radix Achyranthis Bidentatae 47g Rhizoma Chuanxiong 100g
Radix Cynanchi Paniculati 47g Radix Angelicae Dahuricae 70g Rhizoma Curcumae 100g Radix seu Caulis Parabarii 70g
DALUOSAN 100g Radix Ardisiae punctatae 70g Radix Zanthoxyli 100g Caulis Fibraureae 95g
Fructus Gardeniae 100g rhizoma sparganic 100g Lignum Aquilariae Resinatum 32.5g Camphora 60g Mentholum 65g
2, method for making:
More than 20 simply, except that Camphora, Mentholum, 19 flavors such as all the other Radix Aucklandiae are ground into coarse powder, according to the percolation under fluid extract and the extractum item (an appendix I of Chinese Pharmacopoeia version in 2000 O), make solvent with 75% ethanol, flood after 24 hours, with the speed of the about 3ml of per minute percolation slowly, the collection liquid 9200g that filters, device is preserved in addition; After getting Camphora, Mentholum and adding ethanol 800g and make dissolving,, leave standstill, filter, promptly with the above-mentioned liquid mixing of filtering.
Embodiment 3
Adopt the tincture of embodiment 1 to carry out pharmacodynamic study:
1. detumescence effect
6 of every group of Japan large ear rabbits play cropping in the 8cm zone with have sharp ears, put freezing 70s in the freezing tank (18 ± 1 ℃), after freezing 24 hours, begin administration at freezing place, totally 3 groups of administration groups, every group of administration 10ml, 7ml or 5ml, successive administration 7 days.The result shows, compares with the blank group, and the tincture of middle and high dose delivery example 1 obviously alleviates the red and swollen inflammatory reaction of cold injury tissue, prevents that blister from producing and tissue necrosis.This prompting, the tincture of embodiment 1 has the trend of treatment chilblain.
2. to the influence of the rabbit ear perfusion flow that exsomatizes
5 of every group of Japan large ear rabbits, the dosage of the tincture of embodiment 1 is 5ml or 10ml.The rabbit ear that make to exsomatize, the perfusion krebs solution is 10 minutes before administration, after the administration (every rabbit ear is smeared 5ml or 10ml) 10 minutes, 20 minutes, 30 minutes, the perfusion flow of 40 minutes and 60 minutes measurement rabbit ears.The result shows, the rabbit ear was smeared behind the repercussive and analgesic tincture 20 minutes, and rabbit ear perfusion flow is obviously greater than before the administration.This prompting, the tincture of embodiment 1 has blood vessel dilating, the effect of blood circulation promoting.
3. analgesic effect
12 of every group of mices, male and female half and half.With the qualified mice of hot plate method (55 ℃) screening pain threshold, smear the metapedes administration continuous 3 times, each 2 hours at interval, each 1ml.After the last administration 0.5 hour, measure pain threshold.The result shows, compares with the blank group, and administration group mice pain threshold obviously increases.This prompting, the tincture of embodiment 1 has significant analgesia role.
4. antiinflammatory action
12 of every group of mices, male and female half and half.Dimethylbenzene 0.05ml is applied to two sides, mouse right ear front and back, and left ear is not coated with in contrast.Cause scorching back 30 minutes, causing 3 coatings of scorching punishment, each 2 hours at interval.After the last administration 2 hours, relatively two ears are with the weight difference of position homalographic auricle.The result shows, compares with matched group, and administration group mice auricle swelling degree obviously alleviates.This prompting, the local tincture of embodiment 1 that uses has antiinflammatory action.
Pharmacodynamic experiment shows before clinical, the local effect of using repercussive and analgesic tincture to have detumescence, antiinflammatory, pain relieving and blood circulation promoting.This prompting, the tincture of embodiment 1 has the potentiality of treatment chilblain clinically.
Embodiment 4
Clinical observation on the therapeutic effect
One. case is selected:
Collect 1 degree chilblain (being local no blister of chilblain or necrosis) patient's 90 examples and set up matched group 90 examples simultaneously for the treatment group.Aspects such as treatment group and matched group patient sex, age and the state of an illness are basic identical.Two groups of no significant differences of contrast, P>0.05 has comparability.
Two, diagnostic criteria:
(1), Western medicine diagnose standard:
1. the cold injury history is arranged, mostly occur in low-temperature cold season;
2. be the locality chilblain, mainly betide health tip and exposure portion such as the back of the hand, heel, auricle, nose;
3. the chilblain place is obviously red and swollen, conscious pain or have an itch;
(2), Syndrome in TCM marquis diagnostic criteria: syndrome of coagulation cold due to blood deficiency
Syndrome: coldness of the body with chills, the local pain happiness is warm.Light red tongue is and dim, and tongue is white, deep-thready pulse.
(3), include standard in:
1, meets the Western medicine diagnose standard;
2, meet Syndrome in TCM marquis diagnostic criteria;
3, patient age: 18~60 years old;
4, treatment was not used the medicine relevant with primary disease in preceding 7 days;
(4), exclusion standard:
1, gestation or women breast-feeding their children;
2, allergic constitution or to this medicine allergy sufferers;
3, be associated with serious primary disease such as cardiovascular and cerebrovascular vessel, liver, kidney or hemopoietic system, psychotic;
4, there is epidermis breakage person the chilblain part;
5, do not meet other cases of the standard of including in;
Two, Therapeutic Method:
The treatment group: the tincture that gives embodiment 1 is wiped the affected part in right amount, 3~5 times/day;
Matched group: every day, temperature was applied the affected part for several times, did not give other drug and handled;
Three, efficacy determination
1, clinical complete: clinical symptoms, sign disappear or basic the disappearance;
2, produce effects: clinical symptoms, sign are obviously improved;
3, effective: clinical symptoms, sign all take a favorable turn;
4, invalid: clinical symptoms, sign do not have improvement, even increase the weight of;
Four, clinical effectiveness:
1, treat result after 7 days:
Group (routine number) Recovery rate (%/routine number) Obvious effective rate (%/routine number) Effective percentage (%/routine number) Inefficiency (%/routine number) Total effective rate (%/routine number)
Treatment group (90) 18.9/17 36.7/33 38.9/35 5.6/5 94.4/85
Matched group (90) 1.1/1 11.1/10 14.4/13 73.3/66 26.7/24
The data contrast P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
The result shows: treat after 7 days the treatment group and compare with the every data of matched group and significant difference is all arranged, P>0.05
2, treat result after 14 days:
Group (routine number) Recovery rate (%/routine number) Obvious effective rate (%/routine number) Effective percentage (%/routine number) Inefficiency (%/routine number) Total effective rate (%/routine number)
Treatment group (90) 48.9/44 34.4/31 15.6/14 1.1/1 98.9/89
Matched group (90) 10.0/9 24.4/22 22.2/20 43.3/39 56.7/24
The data contrast P>0.05 P<0.05 P<0.05 P>0.05 P>0.05
The result shows: treat that treatment group and matched group relatively have significant difference in recovery rate, total effective rate data, P>0.05 after 14 days
Five, the tincture of conclusion: embodiment 1 can effectively be treated I degree chilblain, and total obvious effective rate and total effective rate reach 55.6% and 94.4% respectively after treating 7 days; Total obvious effective rate and total effective rate reach 83.3% and 98.9% respectively after treating 14 days.

Claims (3)

1. the application of the pharmaceutical composition of following portions by weight in preparation treatment chilblain disease medicine:
1~100 part of 1~100 part of Herba Asari of 1~100 portion of Herba Schizonepetae of 1~100 part of Radix Saposhnikoviae of the Radix Aucklandiae
1~100 part of 1~100 part of Rhizoma Chuanxiong of 1~100 part of Radix Achyranthis Bidentatae of 1~100 part of Ramulus Cinnamomi of Cortex Acanthopancis
1~200 part of 1~100 part of Radix seu Caulis Parabarii of 1~200 part of Rhizoma Curcumae of 1~100 part of Radix Angelicae Dahuricae of Radix Cynanchi Paniculati
1~200 part of 1~300 portion of Caulis Fibraureae of 1~200 portion of Radix Zanthoxyli of 1~300 part of Radix Ardisiae punctatae of DALUOSAN
1~100 part of 1~100 part of Camphora of 1~200 portion of Lignum Aquilariae Resinatum of 1~300 part of rhizoma sparganic of Fructus Gardeniae
1~100 part of Mentholum.
2. application according to claim 1 is characterized in that, parts by weight are:
47 parts of 47 parts of Herba Asaris of 47 portions of Herba Schizonepetae of 47 parts of Radix Saposhnikoviaes of the Radix Aucklandiae
47 parts of 47 parts of Rhizoma Chuanxiongs of 47 parts of Radix Achyranthis Bidentataes of 47 parts of Ramulus Cinnamomi of Cortex Acanthopancis
70 parts of 47 parts of Radix seu Caulis Parabarii of 70 parts of Rhizoma Curcumae of 47 parts of Radixs Angelicae Dahuricae of Radix Cynanchi Paniculati
95 parts of 100 portions of Caulis Fibraureaes of 70 portions of Radix Zanthoxylis of 100 parts of Radix Ardisiae punctatae of DALUOSAN
55 parts of 32.5 parts of Camphoras of 70 portions of Lignum Aquilariae Resinatum of 100 parts of rhizoma sparganic of Fructus Gardeniae
55 parts of Mentholums.
3. application according to claim 1, its feature like this, parts by weight are:
Radix Aucklandiae 47g Radix Saposhnikoviae 100g Herba Schizonepetae 47g Herba Asari 47g
Cortex Acanthopancis 100g Ramulus Cinnamomi 47g Radix Achyranthis Bidentatae 47g Rhizoma Chuanxiong 100g
Radix Cynanchi Paniculati 47g Radix Angelicae Dahuricae 70g Rhizoma Curcumae 100g Radix seu Caulis Parabarii 70g
DALUOSAN 100g Radix Ardisiae punctatae 70g Radix Zanthoxyli 100g Caulis Fibraureae 95g
Fructus Gardeniae 100g rhizoma sparganic 100g Lignum Aquilariae Resinatum 32.5g Camphora 60g
Mentholum 65g.
CNB2005100256894A 2005-05-09 2005-05-09 Application of composition for preparing medicine to treat chilblain disease Expired - Fee Related CN100444887C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100256894A CN100444887C (en) 2005-05-09 2005-05-09 Application of composition for preparing medicine to treat chilblain disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100256894A CN100444887C (en) 2005-05-09 2005-05-09 Application of composition for preparing medicine to treat chilblain disease

Publications (2)

Publication Number Publication Date
CN1861184A true CN1861184A (en) 2006-11-15
CN100444887C CN100444887C (en) 2008-12-24

Family

ID=37388770

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100256894A Expired - Fee Related CN100444887C (en) 2005-05-09 2005-05-09 Application of composition for preparing medicine to treat chilblain disease

Country Status (1)

Country Link
CN (1) CN100444887C (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101954058A (en) * 2010-09-13 2011-01-26 李绪玲 Medicament for treating pernio
CN101991811B (en) * 2009-08-26 2012-02-22 广西玉林制药有限责任公司 Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof
CN102526310A (en) * 2012-01-16 2012-07-04 李仁君 Chinese medicinal formulation for treating cold injury
CN101757522B (en) * 2008-12-17 2013-06-12 重庆医药工业研究院有限责任公司 Swelling reducing and pain easing gel and preparation method thereof
CN101766724B (en) * 2008-12-31 2013-08-14 广西壮族自治区花红药业股份有限公司 Chinese medicine preparation for treating traumatic injury and rheumatic pain and preparation method thereof
CN110279829A (en) * 2019-06-28 2019-09-27 广西壮族自治区花红药业股份有限公司 Swelling and pain relieving composition is preparing the purposes in medicine for treaching hemorrhoie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242804C (en) * 2003-01-30 2006-02-22 成都利尔药业有限公司 External used medicine for traumatic injury and preparation thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757522B (en) * 2008-12-17 2013-06-12 重庆医药工业研究院有限责任公司 Swelling reducing and pain easing gel and preparation method thereof
CN101766724B (en) * 2008-12-31 2013-08-14 广西壮族自治区花红药业股份有限公司 Chinese medicine preparation for treating traumatic injury and rheumatic pain and preparation method thereof
CN101991811B (en) * 2009-08-26 2012-02-22 广西玉林制药有限责任公司 Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof
CN101954058A (en) * 2010-09-13 2011-01-26 李绪玲 Medicament for treating pernio
CN102526310A (en) * 2012-01-16 2012-07-04 李仁君 Chinese medicinal formulation for treating cold injury
CN110279829A (en) * 2019-06-28 2019-09-27 广西壮族自治区花红药业股份有限公司 Swelling and pain relieving composition is preparing the purposes in medicine for treaching hemorrhoie
CN110279829B (en) * 2019-06-28 2023-07-14 广西壮族自治区花红药业集团股份公司 Application of detumescence and acesodyne composition in preparing medicament for treating hemorrhoids

Also Published As

Publication number Publication date
CN100444887C (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CN1836720A (en) Chinese medicine composition for treating arthritis or gout and preparing method thereof
CN1861163A (en) Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process
CN1899500A (en) Acne clearing decoction
CN1861184A (en) Application of composition for preparing medicine to treat chilblain disease
CN1813955A (en) Medicine for treating tympanitis and otitis externa, and preparing method
CN1883552A (en) A Chinese medicine for treating mastopathy and method for preparing same
CN1954866A (en) Medicine for treating odontopathy and its preparation method
CN1283309C (en) Pure medicated wine
CN102579807B (en) Chinese medicine composition for treating dental ulcer
CN104524247B (en) One treats migrainous medical composition and its use
CN1864730A (en) A cancer-treating medicine
CN102755480A (en) External pain-relieving medicament and preparation method thereof
CN1478525A (en) Medicated wine for treating traumatic injury
CN1318378A (en) Heat syndrome treating Chinese medicine
CN101053612A (en) External applied traditional Chinese medicine vagina cleaning agent for curing gynecopathy and vagina cleaning ointment thereof
CN1274352C (en) Plaster for treating hyperosteogeny, protrusion of interverterbral disc, arthritis and periarthritis of shoulder joint and its prepn.
CN100337644C (en) Chinese medicine for treating peptic ulcer and its prepn process
CN1215595A (en) External use medicine for treating soft tissue injury and its producing method
CN1843441A (en) Rheumatism-eliminating collaterals-dredging externally applied plaster
CN102764360A (en) Traditional Chinese medicine composition for treating acute cystitis
CN1186067C (en) Medicine for curing acute injury of muscle and tendon and its preparation method
CN1293897C (en) Burn and scald treating powder
CN105079648A (en) Medicine for preventing and treating myopia
CN1857425A (en) Headache treating medicine
CN1733147A (en) Chinese traditional medicine for curing soft tissue pains and process for preparing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081224

Termination date: 20120509